1. Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther. 2008;117(3):393–405.
2. Feldman D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002;50(Suppl S1):25–37.
3. Keicho N, Kudoh S, Yotsumoto H, Akagawa KS. Erythromycin promotes monocyte to macrophage differentiation. J Antibiot (Tokyo). 1994;47(1):80–9.
4. Sugawara A, Sueki A, Hirose T, Nagai K, Gouda H, Hirono S, et al. Novel 12-membered non-antibiotic macrolides from erythromycin a; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents. Bioorg Med Chem Lett. 2011;21(11):3373–6.
5. Kricker J, Gardarsson F, Lehmann F, Bech M, Gudjonsson T, Page C, et al. Inhibition of neutrophilic inflammation by targeting the airway epithelial barrier with EP395. Eur Respir J. 2022;60:312.